OrthoPediatrics price target raised to $34 from $32 at Stifel

Stifel raised the firm’s price target on OrthoPediatrics to $34 from $32 and keeps a Buy rating on the shares. The firm notes that OrthoPediatrics delivered a largely as-expected quarter, with Q4 in-line with the preannouncement and reiterated 2024 guide. Still, multiple new product launches, the Boston O&P acquisition integration, and improving macro environment seem to argue positively for a favorable KIDS 2024 setup, potential for continued double-digit top-line growth, and opportunity for upside as the year unfolds, Stifel says.